首页 > 最新文献

Case Reports in Oncological Medicine最新文献

英文 中文
Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors. 抗白细胞介素-6受体抗体(Tocilizumab)治疗继发免疫检查点抑制剂的噬血细胞综合征患者的反应
IF 0.9 Q4 ONCOLOGY Pub Date : 2021-02-12 eCollection Date: 2021-01-01 DOI: 10.1155/2021/6631859
Alejandro Olivares-Hernández, Luis Figuero-Pérez, María A Amores Martín, Lorena Bellido Hernández, Laura Mezquita, María Del Rosario Vidal Tocino, Félix López Cadenas, Felipe Gómez-Caminero López, Roberto A Escala-Cornejo, Juan Jesús Cruz Hernández

Background. Immunotherapy represents one of the fundamental treatments in the management of some types of cancer, especially malignant melanoma. Toxicity derived from increased immune system activity can manifest in multiple organs and systems. We present a case of hematological toxicity, manifested as hemophagocytic syndrome (HPS), which was successfully treated with an anti-interleukin-6 antibody (tocilizumab). Case Report. This case presents a 75-year-old woman diagnosed with metastatic choroidal melanoma, refractory to several lines of treatment. After the failure of the previous lines, ipilimumab was started. After the third dose, she developed grade 2 thrombocytopenia and anemia accompanied by elevated levels of ferritin, triglycerides, and decreased fibrinogen. Hemophagocytosis was observed in the bone marrow biopsy, and a PET-CT showed splenomegaly with increased metabolism. Treatment was based on high doses of corticosteroids and tocilizumab. Four days after the start of treatment, progressive clinical and analytical improvement was observed, achieving total remission of the condition. Discussion. HPS induced by immunotherapy is due to an immunorelated cytokine storm syndrome (CSS). The administration of the anti-interleukin-6 receptor antibody drug acted on this cytokine cascade, leading to stabilization and subsequent remission. For this reason, the use of tocilizumab should be part of the immunotherapy-induced HPS treatment algorithm.

背景。免疫疗法是治疗某些类型癌症的基本疗法之一,尤其是恶性黑色素瘤。免疫系统活性增加引起的毒性可在多个器官和系统中表现出来。我们提出一例血液毒性,表现为噬血细胞综合征(HPS),这是成功的治疗与抗白细胞介素-6抗体(托珠单抗)。病例报告。这个病例是一位75岁的女性,被诊断为转移性脉络膜黑色素瘤,对几种治疗方法都难治。在之前的系列失败后,ipilimumab开始了。第三次给药后,患者出现2级血小板减少症和贫血,并伴有铁蛋白、甘油三酯水平升高和纤维蛋白原降低。骨髓活检显示噬血细胞增多,PET-CT显示脾肿大,代谢增加。治疗基于高剂量皮质类固醇和托珠单抗。治疗开始4天后,观察到临床和分析进展改善,达到病情完全缓解。讨论。免疫治疗诱导的HPS是由免疫相关细胞因子风暴综合征(CSS)引起的。抗白细胞介素-6受体抗体药物作用于细胞因子级联,导致稳定和随后的缓解。因此,tocilizumab的使用应该成为免疫治疗诱导的HPS治疗算法的一部分。
{"title":"Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors.","authors":"Alejandro Olivares-Hernández,&nbsp;Luis Figuero-Pérez,&nbsp;María A Amores Martín,&nbsp;Lorena Bellido Hernández,&nbsp;Laura Mezquita,&nbsp;María Del Rosario Vidal Tocino,&nbsp;Félix López Cadenas,&nbsp;Felipe Gómez-Caminero López,&nbsp;Roberto A Escala-Cornejo,&nbsp;Juan Jesús Cruz Hernández","doi":"10.1155/2021/6631859","DOIUrl":"https://doi.org/10.1155/2021/6631859","url":null,"abstract":"<p><p><i>Background</i>. Immunotherapy represents one of the fundamental treatments in the management of some types of cancer, especially malignant melanoma. Toxicity derived from increased immune system activity can manifest in multiple organs and systems. We present a case of hematological toxicity, manifested as hemophagocytic syndrome (HPS), which was successfully treated with an anti-interleukin-6 antibody (tocilizumab). <i>Case Report</i>. This case presents a 75-year-old woman diagnosed with metastatic choroidal melanoma, refractory to several lines of treatment. After the failure of the previous lines, ipilimumab was started. After the third dose, she developed grade 2 thrombocytopenia and anemia accompanied by elevated levels of ferritin, triglycerides, and decreased fibrinogen. Hemophagocytosis was observed in the bone marrow biopsy, and a PET-CT showed splenomegaly with increased metabolism. Treatment was based on high doses of corticosteroids and tocilizumab. Four days after the start of treatment, progressive clinical and analytical improvement was observed, achieving total remission of the condition. <i>Discussion</i>. HPS induced by immunotherapy is due to an immunorelated cytokine storm syndrome (CSS). The administration of the anti-interleukin-6 receptor antibody drug acted on this cytokine cascade, leading to stabilization and subsequent remission. For this reason, the use of tocilizumab should be part of the immunotherapy-induced HPS treatment algorithm.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2021 ","pages":"6631859"},"PeriodicalIF":0.9,"publicationDate":"2021-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25402876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Reconstruction with Total Scapular Reverse Total Shoulder Endoprosthesis after Radical Tumor Excision. 肿瘤根治性切除后全肩胛骨反向全肩关节内假体重建。
IF 0.9 Q4 ONCOLOGY Pub Date : 2021-01-25 eCollection Date: 2021-01-01 DOI: 10.1155/2021/1968621
Michael J Harvey, Howard G Rosenthal

Malignant musculoskeletal tumors about the shoulder girdle region involving the scapula are fairly rare, but when diagnosed, challenging and complex surgical treatment may be warranted with the primary goal of improving patient survival. These tumors are typically extensive and infiltrative at the time of presentation, requiring radical resection to achieve margins and obtain local tumor control. Historically, forequarter amputation or flail extremity were the mainstays of treatment in these cases. Presently, with recent advances in diagnostics, imaging, adjuvant therapies, and surgical treatment, many patients presenting with malignant tumors involving the scapula are candidates for limb salvage surgery. Reconstruction with endoprosthesis seems to have gained acceptance as the preferred surgical treatment for such lesions, as this intervention has resulted in improved postoperative function and cosmesis, with an acceptable complication rate. We present our experience with recent advancement in these surgical efforts in the form of shoulder girdle reconstruction with total scapular reverse total shoulder prosthesis after radical tumor excision.

累及肩胛骨的肩带区恶性肌肉骨骼肿瘤相当罕见,但一旦确诊,可能需要具有挑战性和复杂的手术治疗,其主要目标是提高患者的生存率。这些肿瘤在出现时通常是广泛和浸润的,需要根治性切除以达到边缘和获得局部肿瘤控制。历史上,前肢截肢或连枷肢是治疗这些病例的主要方法。目前,随着诊断、影像学、辅助治疗和外科治疗的最新进展,许多患有累及肩胛骨的恶性肿瘤的患者都是肢体保留手术的候选人。假体重建似乎已被接受为此类病变的首选手术治疗方法,因为这种干预措施改善了术后功能和美观,并发症发生率也在可接受范围内。我们介绍了我们在根治性肿瘤切除后肩胛骨反向全肩关节假体重建肩带手术方面的最新进展。
{"title":"Reconstruction with Total Scapular Reverse Total Shoulder Endoprosthesis after Radical Tumor Excision.","authors":"Michael J Harvey,&nbsp;Howard G Rosenthal","doi":"10.1155/2021/1968621","DOIUrl":"https://doi.org/10.1155/2021/1968621","url":null,"abstract":"<p><p>Malignant musculoskeletal tumors about the shoulder girdle region involving the scapula are fairly rare, but when diagnosed, challenging and complex surgical treatment may be warranted with the primary goal of improving patient survival. These tumors are typically extensive and infiltrative at the time of presentation, requiring radical resection to achieve margins and obtain local tumor control. Historically, forequarter amputation or flail extremity were the mainstays of treatment in these cases. Presently, with recent advances in diagnostics, imaging, adjuvant therapies, and surgical treatment, many patients presenting with malignant tumors involving the scapula are candidates for limb salvage surgery. Reconstruction with endoprosthesis seems to have gained acceptance as the preferred surgical treatment for such lesions, as this intervention has resulted in improved postoperative function and cosmesis, with an acceptable complication rate. We present our experience with recent advancement in these surgical efforts in the form of shoulder girdle reconstruction with total scapular reverse total shoulder prosthesis after radical tumor excision.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2021 ","pages":"1968621"},"PeriodicalIF":0.9,"publicationDate":"2021-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25354221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Syndrome of Inappropriate Antidiuretic Hormone in Esophageal Cancer Patient. 食管癌患者抗利尿激素不适宜综合征。
IF 0.9 Q4 ONCOLOGY Pub Date : 2021-01-19 eCollection Date: 2021-01-01 DOI: 10.1155/2021/8131834
Rahmawati Minhajat, Andi Fachruddin Benyamin, Andi Makbul Aman, Syakib Bakri

Syndrome of inappropriate antidiuretic hormone (SIADH) is a disorder of fluid and sodium balance characterized by hypotonic hyponatremia, low plasma osmolality, and increased urine osmolality caused by excessive release of antidiuretic hormone (ADH). Malignancy is one of the most common causes of SIADH, but SIADH in esophageal carcinoma is very rarely reported. In this case report, a 74-year-old male patient of moderate differentiation of squamous cell esophageal carcinoma had a recurrent electrolyte balance disorder despite repeated corrections. The patient experienced improvement after fluid restriction and drug administration.

不适当的抗利尿激素综合征(SIADH)是一种以低渗性低钠血症、低血浆渗透压和尿渗透压升高为特征的液体和钠平衡紊乱,由过量释放抗利尿激素(ADH)引起。恶性肿瘤是SIADH最常见的病因之一,但食管癌的SIADH很少报道。在本病例报告中,74岁男性中度分化鳞状细胞食管癌患者反复出现电解质平衡紊乱,尽管多次纠正。患者在限制液体和给药后病情有所改善。
{"title":"Syndrome of Inappropriate Antidiuretic Hormone in Esophageal Cancer Patient.","authors":"Rahmawati Minhajat,&nbsp;Andi Fachruddin Benyamin,&nbsp;Andi Makbul Aman,&nbsp;Syakib Bakri","doi":"10.1155/2021/8131834","DOIUrl":"https://doi.org/10.1155/2021/8131834","url":null,"abstract":"<p><p>Syndrome of inappropriate antidiuretic hormone (SIADH) is a disorder of fluid and sodium balance characterized by hypotonic hyponatremia, low plasma osmolality, and increased urine osmolality caused by excessive release of antidiuretic hormone (ADH). Malignancy is one of the most common causes of SIADH, but SIADH in esophageal carcinoma is very rarely reported. In this case report, a 74-year-old male patient of moderate differentiation of squamous cell esophageal carcinoma had a recurrent electrolyte balance disorder despite repeated corrections. The patient experienced improvement after fluid restriction and drug administration.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2021 ","pages":"8131834"},"PeriodicalIF":0.9,"publicationDate":"2021-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25325195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synchronous Occurrence of Splenic Pleomorphic Mantle Cell Lymphoma and Esophageal Adenocarcinoma with Overexpression of BCL1 Protein. 脾多形性套细胞淋巴瘤和食管腺癌同时发生与BCL1蛋白过表达。
IF 0.9 Q4 ONCOLOGY Pub Date : 2020-12-21 eCollection Date: 2020-01-01 DOI: 10.1155/2020/8888829
Dominik Dabrowski, Roberto F Silva, Michael Constantinescu, Rodney E Shackelford, Nestor Dela Cruz, Eric X Wei

Synchronous occurrences of mantle cell lymphoma (MCL), or intermediate lymphocytic lymphoma, and other malignancies are rare. Such cases present diagnostic and especially therapeutic challenges, making them of particular interest to study. We report a case of synchronic MCL and an esophageal tumor in an elderly male patient. Morphologically, the tumors were classified as splenic pleomorphic MCL and adenocarcinoma of the esophagus occurring concurrently. The pleomorphic MCL mimicked diffuse large B cell lymphoma (DLBCL) but lacked larger centroblast- or immunoblast-like cells. Curiously, both tumors overexpressed cyclin D1 by immunohistochemistry. This is an important feature that distinguishes MCL pathologically from two of its closest entities in the differential diagnosis: chronic lymphocytic leukemia and DLBCL, the latter of which mantle cells cannot transform into. The lymphoproliferation revealed IGH/CCND1 translocation by FISH, but the esophageal adenocarcinoma only showed CCND1 aneuploidy without break-apart signals. Since the gastrointestinal (GI) tract is a common site of extranodal involvement by MCL and lymphomatous polyposis can present as GI polyps, adequate care was taken to differentiate the esophageal adenocarcinoma from advanced stagings of MCL, as well as metastatic adenocarcinoma. Despite numerous immunohistochemical stainings studied, only BCL1 was demonstrated to have partial overlap in both tumors. The patient underwent esophagectomy and splenectomy. A subsequent metastatic primary lung squamous cell carcinoma was diagnosed, after which the patient expired. MCL typically presents at an advanced stage and has been deemed incurable with a prognosis of only several years. It is unclear whether the patient succumbed to complications of his MCL or the metastatic squamous cell carcinoma. Furthermore, he was lost to follow-up for a year and only received treatment after his third cancer was diagnosed. We have reviewed previous reports of synchronic mantle cell lymphoma and other solid tumors or hematological malignancies in the literature.

套细胞淋巴瘤(MCL)或中间淋巴细胞淋巴瘤和其他恶性肿瘤的同时发生是罕见的。这些病例提出了诊断和治疗方面的挑战,使他们特别感兴趣的研究。我们报告一例同时性MCL和食道肿瘤在一个老年男性病人。形态学上,肿瘤分为脾多形性MCL和食管腺癌合并发生。多形性MCL模拟弥漫性大B细胞淋巴瘤(DLBCL),但缺乏较大的成中心细胞或免疫母细胞样细胞。奇怪的是,通过免疫组化,两种肿瘤都过表达cyclin D1。这是一个重要的特征,从病理学上区分MCL与两种最接近的鉴别诊断实体:慢性淋巴细胞白血病和DLBCL,后者的套细胞不能转化。淋巴增生FISH显示IGH/CCND1易位,而食管腺癌仅显示CCND1非整倍体,无分离信号。由于胃肠道是MCL累及结外的常见部位,而淋巴瘤性息肉病可表现为胃肠道息肉,因此需要充分注意区分食管腺癌与晚期MCL以及转移性腺癌。尽管研究了大量的免疫组织化学染色,但只有BCL1在两种肿瘤中被证明有部分重叠。患者行食管切除术和脾切除术。随后被诊断为转移性原发性肺鳞状细胞癌,之后患者死亡。MCL通常出现在晚期,被认为是无法治愈的,预后只有几年。目前尚不清楚患者是否死于MCL并发症或转移性鳞状细胞癌。此外,他失去了一年的随访,直到他的第三次癌症被诊断出来后才接受治疗。我们回顾了文献中关于同时性套细胞淋巴瘤和其他实体肿瘤或血液系统恶性肿瘤的先前报道。
{"title":"Synchronous Occurrence of Splenic Pleomorphic Mantle Cell Lymphoma and Esophageal Adenocarcinoma with Overexpression of BCL1 Protein.","authors":"Dominik Dabrowski,&nbsp;Roberto F Silva,&nbsp;Michael Constantinescu,&nbsp;Rodney E Shackelford,&nbsp;Nestor Dela Cruz,&nbsp;Eric X Wei","doi":"10.1155/2020/8888829","DOIUrl":"https://doi.org/10.1155/2020/8888829","url":null,"abstract":"<p><p>Synchronous occurrences of mantle cell lymphoma (MCL), or intermediate lymphocytic lymphoma, and other malignancies are rare. Such cases present diagnostic and especially therapeutic challenges, making them of particular interest to study. We report a case of synchronic MCL and an esophageal tumor in an elderly male patient. Morphologically, the tumors were classified as splenic pleomorphic MCL and adenocarcinoma of the esophagus occurring concurrently. The pleomorphic MCL mimicked diffuse large B cell lymphoma (DLBCL) but lacked larger centroblast- or immunoblast-like cells. Curiously, both tumors overexpressed cyclin D1 by immunohistochemistry. This is an important feature that distinguishes MCL pathologically from two of its closest entities in the differential diagnosis: chronic lymphocytic leukemia and DLBCL, the latter of which mantle cells cannot transform into. The lymphoproliferation revealed IGH/CCND1 translocation by FISH, but the esophageal adenocarcinoma only showed CCND1 aneuploidy without break-apart signals. Since the gastrointestinal (GI) tract is a common site of extranodal involvement by MCL and lymphomatous polyposis can present as GI polyps, adequate care was taken to differentiate the esophageal adenocarcinoma from advanced stagings of MCL, as well as metastatic adenocarcinoma. Despite numerous immunohistochemical stainings studied, only BCL1 was demonstrated to have partial overlap in both tumors. The patient underwent esophagectomy and splenectomy. A subsequent metastatic primary lung squamous cell carcinoma was diagnosed, after which the patient expired. MCL typically presents at an advanced stage and has been deemed incurable with a prognosis of only several years. It is unclear whether the patient succumbed to complications of his MCL or the metastatic squamous cell carcinoma. Furthermore, he was lost to follow-up for a year and only received treatment after his third cancer was diagnosed. We have reviewed previous reports of synchronic mantle cell lymphoma and other solid tumors or hematological malignancies in the literature.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2020 ","pages":"8888829"},"PeriodicalIF":0.9,"publicationDate":"2020-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38803642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Hepatocellular Carcinoma: First Manifestation as Solitary Humeral Bone Metastasis. 肝细胞癌:首次表现为孤立的肱骨骨转移。
IF 0.6 Q4 ONCOLOGY Pub Date : 2020-12-01 eCollection Date: 2020-01-01 DOI: 10.1155/2020/8254236
Sumera Bukhari, Kristine Ward, Michael Styler

Hepatocellular carcinoma (HCC) most commonly presents with abdominal pain or mass, fever of unknown etiology, weight loss, and decompensation of known liver disease or at an asymptomatic stage through surveillance. Rarely, presenting symptoms can be exclusively related to extrahepatic metastases. Herein, we write a case of a patient with no known liver disease, presenting with a pathological fracture of the proximal humerus bone secondary to a massive solitary metastasis from HCC. This case represents an unusual appendicular skeletal metastasis in a patient with unknown primary HCC, successfully treated with sorafenib. The prognosis of HCC patients with extrahepatic metastasis is poor, and in the presence of bone metastases, the mean survival rate is severely reduced. However, the multikinase inhibitor sorafenib has been the standard of treatment. Recently, there has been developments of other therapeutic class of drugs (i.e., immune check inhibitors), which have shown promising benefits and better side effect profiles. Still, there is a need for further studies, owing to challenges in recognizing cellular and molecular markers.

肝细胞癌(HCC)最常见的症状是腹痛或肿块、病因不明的发热、体重减轻、已知肝病的失代偿或通过监测处于无症状阶段。在极少数情况下,出现的症状可能完全与肝外转移有关。在此,我们记录了一例无已知肝病的患者,其肱骨近端骨病理性骨折是继发于肝癌的巨大单发转移瘤。该病例是原发性不明的 HCC 患者中的一个不常见的阑尾骨骼转移瘤,患者接受索拉非尼治疗后获得成功。有肝外转移的 HCC 患者预后较差,如果出现骨转移,平均生存率会严重下降。然而,多激酶抑制剂索拉非尼一直是治疗的标准药物。最近,其他治疗类药物(即免疫检查抑制剂)也有了新的发展,显示出良好的疗效和更好的副作用。不过,由于在识别细胞和分子标记物方面存在挑战,因此仍需进一步研究。
{"title":"Hepatocellular Carcinoma: First Manifestation as Solitary Humeral Bone Metastasis.","authors":"Sumera Bukhari, Kristine Ward, Michael Styler","doi":"10.1155/2020/8254236","DOIUrl":"10.1155/2020/8254236","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) most commonly presents with abdominal pain or mass, fever of unknown etiology, weight loss, and decompensation of known liver disease or at an asymptomatic stage through surveillance. Rarely, presenting symptoms can be exclusively related to extrahepatic metastases. Herein, we write a case of a patient with no known liver disease, presenting with a pathological fracture of the proximal humerus bone secondary to a massive solitary metastasis from HCC. This case represents an unusual appendicular skeletal metastasis in a patient with unknown primary HCC, successfully treated with sorafenib. The prognosis of HCC patients with extrahepatic metastasis is poor, and in the presence of bone metastases, the mean survival rate is severely reduced. However, the multikinase inhibitor sorafenib has been the standard of treatment. Recently, there has been developments of other therapeutic class of drugs (i.e., immune check inhibitors), which have shown promising benefits and better side effect profiles. Still, there is a need for further studies, owing to challenges in recognizing cellular and molecular markers.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2020 ","pages":"8254236"},"PeriodicalIF":0.6,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38733505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Delays in Diagnosis of Pulmonary Lymphangitic Carcinomatosis due to Benign Presentation. 良性表现对肺淋巴管癌诊断的延误。
IF 0.9 Q4 ONCOLOGY Pub Date : 2020-11-24 eCollection Date: 2020-01-01 DOI: 10.1155/2020/4150924
Swati Pandey, Shishir Ojha

The diagnosis of lymphangitic carcinomatosis is challenging due to the manifestation of nonspecific symptoms and radiographic abnormalities that bear similarity to those of interstitial lung disease. Herein, we report the case of a 53-year-old woman diagnosed with lymphangitic carcinomatosis from metastatic gastric adenocarcinoma, 3 months after her initial presentation.

淋巴管癌的诊断具有挑战性,因为其表现为非特异性症状和影像学异常,与肺间质性疾病相似。在此,我们报告一例53岁的女性,在她最初的表现3个月后,被诊断为转移性胃腺癌的淋巴管癌病。
{"title":"Delays in Diagnosis of Pulmonary Lymphangitic Carcinomatosis due to Benign Presentation.","authors":"Swati Pandey,&nbsp;Shishir Ojha","doi":"10.1155/2020/4150924","DOIUrl":"https://doi.org/10.1155/2020/4150924","url":null,"abstract":"<p><p>The diagnosis of lymphangitic carcinomatosis is challenging due to the manifestation of nonspecific symptoms and radiographic abnormalities that bear similarity to those of interstitial lung disease. Herein, we report the case of a 53-year-old woman diagnosed with lymphangitic carcinomatosis from metastatic gastric adenocarcinoma, 3 months after her initial presentation.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2020 ","pages":"4150924"},"PeriodicalIF":0.9,"publicationDate":"2020-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/4150924","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38694612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Successful Treatment by Surgery and Lenvatinib of a Patient with Adrenal Metastasis of Papillary Thyroid Cancer. 手术加Lenvatinib成功治疗甲状腺乳头状癌肾上腺转移1例。
IF 0.9 Q4 ONCOLOGY Pub Date : 2020-11-05 eCollection Date: 2020-01-01 DOI: 10.1155/2020/2107430
Hajime Nakamura, Kohichi Takada, Kazuyuki Murase, Hiroki Sakamoto, Naotaka Hayasaka, Kazuma Ishikawa, Yuki Ikeda, Makoto Yoshida, Satoshi Iyama, Ko Kobayashi, Tetsuya Shindo, Shintaro Sugita, Koji Miyanishi, Masayoshi Kobune, Naoya Masumori, Junji Kato

Papillary thyroid cancer (PTC) is considered an indolent cancer, but some PTC patients do present with distant metastases and treatment strategies for such patients are not well established. Recently, lenvatinib, an inhibitor of multiple tyrosine kinases, has been introduced to treat patients with advanced PTC but carries a risk of serious adverse events such as hemorrhage. Here, we report a PTC patient with a left adrenal metastasis and lenvatinib-induced hemorrhage who underwent successful surgical resection and was subsequently treated with a lower dose of lenvatinib. The patient has now been in a stable state with no adverse events for nearly two years. This case highlights the importance of surgical resection of metastatic PTC and subsequent lenvatinib therapy, even when the tumor is at an advanced stage.

甲状腺乳头状癌(PTC)被认为是一种惰性癌症,但一些PTC患者确实存在远处转移,并且此类患者的治疗策略尚未建立。最近,lenvatinib(一种多种酪氨酸激酶抑制剂)已被引入治疗晚期PTC患者,但存在出血等严重不良事件的风险。在这里,我们报告了一例伴有左肾上腺转移和lenvatinib引起的出血的PTC患者,他成功地进行了手术切除,随后接受了低剂量的lenvatinib治疗。患者近两年来病情稳定,无不良事件发生。该病例强调了手术切除转移性PTC和随后lenvatinib治疗的重要性,即使肿瘤处于晚期。
{"title":"Successful Treatment by Surgery and Lenvatinib of a Patient with Adrenal Metastasis of Papillary Thyroid Cancer.","authors":"Hajime Nakamura,&nbsp;Kohichi Takada,&nbsp;Kazuyuki Murase,&nbsp;Hiroki Sakamoto,&nbsp;Naotaka Hayasaka,&nbsp;Kazuma Ishikawa,&nbsp;Yuki Ikeda,&nbsp;Makoto Yoshida,&nbsp;Satoshi Iyama,&nbsp;Ko Kobayashi,&nbsp;Tetsuya Shindo,&nbsp;Shintaro Sugita,&nbsp;Koji Miyanishi,&nbsp;Masayoshi Kobune,&nbsp;Naoya Masumori,&nbsp;Junji Kato","doi":"10.1155/2020/2107430","DOIUrl":"https://doi.org/10.1155/2020/2107430","url":null,"abstract":"<p><p>Papillary thyroid cancer (PTC) is considered an indolent cancer, but some PTC patients do present with distant metastases and treatment strategies for such patients are not well established. Recently, lenvatinib, an inhibitor of multiple tyrosine kinases, has been introduced to treat patients with advanced PTC but carries a risk of serious adverse events such as hemorrhage. Here, we report a PTC patient with a left adrenal metastasis and lenvatinib-induced hemorrhage who underwent successful surgical resection and was subsequently treated with a lower dose of lenvatinib. The patient has now been in a stable state with no adverse events for nearly two years. This case highlights the importance of surgical resection of metastatic PTC and subsequent lenvatinib therapy, even when the tumor is at an advanced stage.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2020 ","pages":"2107430"},"PeriodicalIF":0.9,"publicationDate":"2020-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/2107430","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38720786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Diffuse Pancreatic Carcinoma with Hepatic Metastases. 弥漫性胰腺癌伴肝转移。
IF 0.9 Q4 ONCOLOGY Pub Date : 2020-10-30 eCollection Date: 2020-01-01 DOI: 10.1155/2020/8815745
Hoang Quan Nguyen, Ngoc Trinh Thi Pham, Van Trung Hoang, Hoang Anh Thi Van, Chinh Huynh, Duc Thanh Hoang

Pancreatic cancer is one of the seven leading causes of cancer death worldwide. Diffuse pancreatic carcinoma is very rare and underreported in the literature. Many advances have been made in the diagnosis and management of pancreatic cancer. However, most pancreatic cancer cases are detected at the terminal or metastatic stages. Therefore, timely diagnosis and therapeutic management are desirable goals for this disease. Although the proliferation of pancreatic cancer has been reduced by intervention, more work is needed to treat and prevent the disease. The purpose of this article is to present a case of a 54-year-old male with pancreatic cancer and to review the epidemiology, diagnosis, management, and prevention of pancreatic tumors in general as well as pancreatic carcinoma in particular.

胰腺癌是全球癌症死亡的七大主要原因之一。弥漫性胰腺癌在文献中非常罕见且报道不足。胰腺癌的诊断和治疗已经取得了许多进展。然而,大多数胰腺癌病例在晚期或转移阶段被发现。因此,及时诊断和治疗是本病的理想目标。虽然通过干预已经减少了胰腺癌的增殖,但在治疗和预防这种疾病方面还需要做更多的工作。本文的目的是提出一个54岁男性胰腺癌的病例,并回顾胰腺肿瘤的流行病学,诊断,管理和预防,特别是胰腺癌。
{"title":"Diffuse Pancreatic Carcinoma with Hepatic Metastases.","authors":"Hoang Quan Nguyen,&nbsp;Ngoc Trinh Thi Pham,&nbsp;Van Trung Hoang,&nbsp;Hoang Anh Thi Van,&nbsp;Chinh Huynh,&nbsp;Duc Thanh Hoang","doi":"10.1155/2020/8815745","DOIUrl":"https://doi.org/10.1155/2020/8815745","url":null,"abstract":"<p><p>Pancreatic cancer is one of the seven leading causes of cancer death worldwide. Diffuse pancreatic carcinoma is very rare and underreported in the literature. Many advances have been made in the diagnosis and management of pancreatic cancer. However, most pancreatic cancer cases are detected at the terminal or metastatic stages. Therefore, timely diagnosis and therapeutic management are desirable goals for this disease. Although the proliferation of pancreatic cancer has been reduced by intervention, more work is needed to treat and prevent the disease. The purpose of this article is to present a case of a 54-year-old male with pancreatic cancer and to review the epidemiology, diagnosis, management, and prevention of pancreatic tumors in general as well as pancreatic carcinoma in particular.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2020 ","pages":"8815745"},"PeriodicalIF":0.9,"publicationDate":"2020-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/8815745","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38605770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Incidence of Gastrointestinal Neuroendocrine Tumor: Case Series, Armed Forces Hospital Southern Region, Hospital-Based Tumor Board Registry. 胃肠神经内分泌肿瘤的发病率:病例系列,南区武装部队医院,医院肿瘤委员会登记。
IF 0.9 Q4 ONCOLOGY Pub Date : 2020-10-20 eCollection Date: 2020-01-01 DOI: 10.1155/2020/8819392
Abdullah Mohammed Albishi, Ahmed Mostafa Mohamed Mostafa, Hatim Mahgoub Ali, Yahia Atiah Alhagawi, Mohamed F Bazeed, Mahmoud R A Hussein, Elshfeia Elhag Mohmed Ali Aloba, Ahmed Youssef Aboelyazid

Neuroendocrine tumors are aggressive and rare tumors which can occur almost everywhere in the body. The annual incidence of neuroendocrine tumors is 2.5-5 per 100000. We report seven cases of gastrointestinal neuroendocrine tumors which were diagnosed and treated at our hospital from the time period of 2016-2018 knowing that the total number of our hospital tumor board cases registry during the same period was 444 cases.

神经内分泌肿瘤是侵袭性和罕见的肿瘤,几乎可以发生在身体的任何地方。神经内分泌肿瘤的年发病率为2.5-5 / 100000。我们报告2016-2018年期间在我院诊治的胃肠道神经内分泌肿瘤7例,了解同期我院肿瘤委员会病例登记总数为444例。
{"title":"Incidence of Gastrointestinal Neuroendocrine Tumor: Case Series, Armed Forces Hospital Southern Region, Hospital-Based Tumor Board Registry.","authors":"Abdullah Mohammed Albishi,&nbsp;Ahmed Mostafa Mohamed Mostafa,&nbsp;Hatim Mahgoub Ali,&nbsp;Yahia Atiah Alhagawi,&nbsp;Mohamed F Bazeed,&nbsp;Mahmoud R A Hussein,&nbsp;Elshfeia Elhag Mohmed Ali Aloba,&nbsp;Ahmed Youssef Aboelyazid","doi":"10.1155/2020/8819392","DOIUrl":"https://doi.org/10.1155/2020/8819392","url":null,"abstract":"<p><p>Neuroendocrine tumors are aggressive and rare tumors which can occur almost everywhere in the body. The annual incidence of neuroendocrine tumors is 2.5-5 per 100000. We report seven cases of gastrointestinal neuroendocrine tumors which were diagnosed and treated at our hospital from the time period of 2016-2018 knowing that the total number of our hospital tumor board cases registry during the same period was 444 cases.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2020 ","pages":"8819392"},"PeriodicalIF":0.9,"publicationDate":"2020-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/8819392","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38561100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Management of Low-Grade Appendiceal Mucinous Neoplasm with Extensive Peritoneal Spread Diagnosed during Pregnancy: Two Case Reports and Literature Review. 妊娠期确诊的伴有腹膜广泛扩散的低级别阑尾黏液性肿瘤的治疗:两例病例报告和文献综述
IF 0.6 Q4 ONCOLOGY Pub Date : 2020-10-15 eCollection Date: 2020-01-01 DOI: 10.1155/2020/8853704
Ekaterina Baron, Vadim Gushchin, Mary Caitlin King, Andrei Nikiforchin, Armando Sardi

Background: Clinical decisions in patients with peritoneal dissemination of low-grade appendiceal mucinous neoplasms (LAMN) diagnosed during pregnancy are challenging. However, their slow progression and favorable prognosis allow deferring definitive treatment until after spontaneous delivery, a reasonable period of breastfeeding, and fertility preservation. Case Presentation. Two pregnant patients were incidentally diagnosed with LAMN and extensive peritoneal spread at 20 weeks gestation and at cesarean section. Treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in both cases was delayed until spontaneous delivery at term and breastfeeding in the first patient and breastfeeding and fertility preservation in the second patient. Both patients remain disease-free for over 5 years, and their children are healthy. The literature review highlights the challenges that physicians face in treating pregnant patients with stage IV appendiceal tumors.

Conclusion: Pregnancy management decisions in patients with peritoneal spread from mucinous appendiceal tumor should be based on understanding the tumor biology and prognosis. Definitive treatment in pregnant patients with favorable tumors, such as LAMN, may be delayed until spontaneous delivery without compromising maternal survival.

背景:对于在妊娠期确诊的腹膜播散低级别阑尾粘液瘤(LAMN)患者,临床决策具有挑战性。然而,这些肿瘤进展缓慢,预后良好,因此可以将最终治疗推迟到自然分娩、合理的哺乳期和生育能力保留之后。病例介绍。两名孕妇在妊娠 20 周剖腹产时意外被诊断出患有 LAMN 和广泛腹膜扩散。两例患者均接受了细胞减灭术和腹腔热化疗,第一例患者推迟到足月自然分娩和母乳喂养,第二例患者推迟到母乳喂养和保留生育力。这两名患者均在 5 年多的时间里没有患病,其子女也很健康。文献综述强调了医生在治疗阑尾肿瘤 IV 期妊娠患者时所面临的挑战:结论:粘液性阑尾肿瘤腹膜扩散患者的妊娠管理决策应基于对肿瘤生物学和预后的了解。对妊娠期肿瘤(如 LAMN)患者的最终治疗可推迟到自然分娩,而不会影响产妇的生存。
{"title":"Management of Low-Grade Appendiceal Mucinous Neoplasm with Extensive Peritoneal Spread Diagnosed during Pregnancy: Two Case Reports and Literature Review.","authors":"Ekaterina Baron, Vadim Gushchin, Mary Caitlin King, Andrei Nikiforchin, Armando Sardi","doi":"10.1155/2020/8853704","DOIUrl":"10.1155/2020/8853704","url":null,"abstract":"<p><strong>Background: </strong>Clinical decisions in patients with peritoneal dissemination of low-grade appendiceal mucinous neoplasms (LAMN) diagnosed during pregnancy are challenging. However, their slow progression and favorable prognosis allow deferring definitive treatment until after spontaneous delivery, a reasonable period of breastfeeding, and fertility preservation. <i>Case Presentation</i>. Two pregnant patients were incidentally diagnosed with LAMN and extensive peritoneal spread at 20 weeks gestation and at cesarean section. Treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in both cases was delayed until spontaneous delivery at term and breastfeeding in the first patient and breastfeeding and fertility preservation in the second patient. Both patients remain disease-free for over 5 years, and their children are healthy. The literature review highlights the challenges that physicians face in treating pregnant patients with stage IV appendiceal tumors.</p><p><strong>Conclusion: </strong>Pregnancy management decisions in patients with peritoneal spread from mucinous appendiceal tumor should be based on understanding the tumor biology and prognosis. Definitive treatment in pregnant patients with favorable tumors, such as LAMN, may be delayed until spontaneous delivery without compromising maternal survival.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2020 ","pages":"8853704"},"PeriodicalIF":0.6,"publicationDate":"2020-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38551509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Case Reports in Oncological Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1